Meningococcal Serogroup A, C, W-135 and Y Conjugated Vaccine:A Cost-Effectiveness Analysis in the Netherlands

Background: In 2002, vaccination with a serogroup C meningococcal conjugate vaccine (MenC) was introduced in the Netherlands for all children aged 14 months. Despite its success, herd immunity may wane over time. Recently, a serogroup A,C,W-135, Y meningococcal conjugate vaccine (MenACWY) was licensed for use in subjects of 12 months of age and above. Objectives: To evaluate the cost-effectiveness of meningococcal vaccination at 14 months and an additional vaccination at the age of 12 years, both with the MenACWY vaccine. Methods: A decision analysis cohort model, with 185,000 Dutch newborns,... Mehr ...